Drug intelligence / Profile preview

SLX-9029

Development stage: Preclinical
Lead developer: Biolexis Therapeutics
Modality: Small Molecules

Overview

SLX-9029 is a novel, selective small molecule inhibitor of Transglutaminase 2 (TGM2) being developed by Biolexis Therapeutics for the treatment of glioblastoma. TGM2 is a calcium-dependent enzyme that facilitates post-translational modifications by cross-linking extracellular matrix (ECM) proteins, thereby stabilizing the tumor microenvironment and contributing to therapeutic resistance. SLX-9029 was identified through Fragment2Lead (F2L) optimization using the MolecuLern fragment library. In preclinical studies, it demonstrated an IC50 of 1.2 µM in cell-free assays and showed efficacy in U138 and U87 glioblastoma cell lines. The compound aims to modulate the tumor microenvironment and enhance immune responses against glioblastoma.

Targets

TGM2 (Tissue Transglutaminase 2)

Beyond the preview

Go deeper on SLX-9029.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLX-9029.

Explore the full profile